ATRA and Carfilzomib in Plasma Cell Myeloma Patients

NCT06536413 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: All-Trans Retinoic Acid (ATRA) Dose 0
DRUG: All-Trans Retinoic Acid (ATRA) Dose -1
DRUG: All-Trans Retinoic Acid (ATRA) Dose 1

Sponsor

The Methodist Hospital Research Institute

Collaborators

[object Object]